Clinical Trial Update: Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating olaparib for efficacy and safety in Chinese patients with metastatic castration-resistant prostate cancer who failed prior h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Olaparib (Olaparib)

Snippet

Sponsor: AstraZeneca | Conditions: Metastatic Castration-resistant Prostate Cancer | Phase 4 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-12-19